Titre A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation
Protocole ID 20170543 (CodeBreaK 100)
ClinicalTrials.gov ID NCT03600883
Type(s) de cancer Poumon non à petites cellules
Tumeurs solides
Phase Phase I-II
Type étude Clinique
Médicament AMG 510
Institution CENTRE UNIVERSITAIRE DE SANTE MCGILL
   SITE GLEN
      1001 boul. Décarie , Montréal, QC, H4A 3J1
Ville Montréal
Investigateur(trice) principal(e) Dr Benjamin Shieh
Coordonnateur(trice) Nicola Raby
 514-934-1934 poste 34095
Statut Fermé
Critètes d'éligibilité
  • Men or women greater than or equal to 18 years old.
  • Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing.
Critètes d'exclusion
  • Active brain metastases from non-brain tumors.
  • Myocardial infarction within 6 months of study day 1.
  • Gastrointestinal (GI) tract disease causing the inability to take oral medication.